Drugs / Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03084380 | Jun 2017 → May 2019 | hepatocellular carcinoma | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03084380 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR)-modified T (CAR-T) cells” NCT03084380 ↗ |
| Route | Intravenous | “intravenous administration of the anti-GPC3 CAR-T cells” NCT03084380 ↗ |
| Target | GPC3 | “anti-GPC3 CAR-T cells” NCT03084380 ↗ |